We can’t show the full text here under this license. Use the link below to read it at the source.
Psychiatric effects of GLP ‐1 receptor agonists: A systematic review of emerging evidence
Mental health effects of GLP-1 receptor drugs: A review of new evidence
AI simplified
Abstract
A systematic review suggests that may have modest antidepressant effects.
- GLP-1 receptor agonists are increasingly recognized for potential neuropsychiatric effects beyond managing blood sugar levels.
- Preliminary evidence indicates potential therapeutic benefits in eating disorders and substance use disorders.
- The association with remains inconsistent and requires further investigation.
- Studies reviewed showed variability in dosing, clinical indications, and the baseline psychiatric status of participants.
- Concerns regarding the impact of GLP-1 receptor agonists on psychiatric symptoms in schizophrenia have not been resolved.
AI simplified
Key numbers
195%
Increase in Major Depressive Disorder Risk
Risk associated with GLP-1RA use in individuals with obesity
0.12
Reduction in Depression Scores
Standardized mean difference from meta-analysis of GLP-1RA users
−8.14
Reduction in Binge Eating Scale Scores
Mean difference in scores among GLP-1RA users compared to controls